- Trial phase
- Phase 3
- Time to market
- If the OPERA-01 Phase 3 trial succeeds, palazestrant could potentially be filed for FDA approval in 2027, with a potential launch in 2028 at the earliest, assuming no regulatory delays.
- Why 8/10
- The next hard, dated catalyst is the SABCS 2026 presentation in December 2026 (combination data), but the truly pivotal binary event is the Phase 3 OPERA-01 topline readout expected in Q1 2027. Palazestrant is Olema's only clinical-stage asset and drives essentially the entire company valuation, making the OPERA-01 readout a make-or-break event. However, since the readout is 3-5 months away (not within 6 months from today), the impactScore is capped at 8 per the rubric.
The next hard catalyst is the SABCS 2026 presentation in December 2026, where Olema will show combination data for palazestrant with ribociclib and for its KAT6 inhibitor OP-3136. The truly binary event is the OPERA-01 Phase 3 monotherapy topline readout, now guided for Q1 2027. A positive readout would validate palazestrant as a potential best-in-class oral SERD/CERAN and likely drive a significant re-rating given the stock's current ~$7 price vs. a ~$36.50 mean analyst target. A negative or mixed result would be severely punishing given the company's high cash burn and near-total dependence on this single asset.
Price Chart
Executive Summary
Palazestrant (OP-1250) is Olema Pharmaceuticals' lead and only clinical-stage drug candidate, an oral small molecule with a dual CERAN/SERD mechanism targeting ER+/HER2- metastatic breast cancer. It is currently being evaluated in two Phase 3 trials: OPERA-01 (monotherapy in 2nd/3rd-line) and OPERA-02 (first-line combination with ribociclib). The pivotal OPERA-01 topline readout is expected in Q1 2027, making this the defining binary catalyst for the company. The stock trades at ~$7.27, down roughly 80% from its 52-week high, with a mean analyst price target of $36.50 (Strong Buy consensus) and very high short interest of ~19.6% of outstanding shares. Near-term catalysts include combination data presentations at SABCS 2026 in December.
How It Works
Palazestrant is an oral (pill) small molecule that attacks estrogen-receptor-positive (ER+) breast cancer through two mechanisms: it completely blocks the estrogen receptor from being activated (complete antagonism, the CERAN mechanism) and it also degrades the receptor protein itself (SERD mechanism). This dual action is designed to more thoroughly shut down estrogen-driven cancer growth than drugs that only do one or the other. It is taken daily as a pill.
Trial Status
Two pivotal Phase 3 trials are underway: OPERA-01 (monotherapy in 2nd/3rd-line ER+/HER2- metastatic breast cancer) completed enrollment in mid-2026 with top-line data expected Q1 2027; OPERA-02 (first-line combination with ribociclib) is actively enrolling. Earlier Phase 1b/2 combination data with ribociclib has been presented at ESMO and SABCS conferences showing encouraging preliminary activity.
The Two-Sided Case
Upcoming Catalysts
- SABCS 2026 (December 2026): Presentation of combination data for palazestrant + ribociclib and OP-3136 preclinical/clinical data
- OPERA-01 Phase 3 topline data readout: Expected Q1 2027 (the primary binary catalyst for the stock)
- OPERA-02 Phase 3 enrollment completion and potential interim updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Olema Oncology PRESS-RELEASE OLMA ·Originating report